Danielle Gatti-Palumbo, PharmD reviews the phase 3 APEX trial evaluating Guselkumab in patients with active psoriatic arthritis (PsA), highlighting its role in reducing inflammation, improving clinical outcomes, and preventing structural joint damage. The discussion emphasizes the importance of early biologic intervention in a disease that can quickly lead to irreversible damage and disability.

Results show that guselkumab significantly improved ACR response rates and inhibited radiographic progression by week 24 compared to placebo, with benefits seen across multiple disease domains including joints, skin, nails, and physical function. With a favorable safety profile and durable efficacy, this IL-23 inhibitor represents a valuable treatment option for clinicians managing PsA and aiming to prevent long-term disease progression.